The biopharmaceutical company said it has discontinued enrollment in a phase 1/2 study evaluating ONCT-216 in patients with relapsed or refractory Ewing sarcoma. Oncternal expects to initiate a phase 3 trial of zilovertamab in Q3.
ONCT shares were down more than 1% Wednesday morning.
Price: 1.15, Change: -0.01, Percent Change: -1.29
|Nordstrom May Benefit From High-Income Consumer Spen...|
|--Melius Research Initiates Coverage of Frontier Gro...|
|Insider Sell: Minerals Technologies|
|--Melius Research Initiates Coverage of Delta Air Li...|
|--Melius Research Initiates Coverage of Allegiant Tr...|